ViroPharma to Develop Intellect Neurosciences’ OX1 for Friedreich’s Ataxia
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 10 (Table of Contents)
Published: 14 Oct-2011
DOI: 10.3833/pdr.v2011.i10.1573 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
ViroPharma has obtained a worldwide licence to certain licensed patents and patent applications relating to Intellect Neurosciences’ clinical-stage antioxidant, OX1, which ViroPharma plans to develop for Friedreich’s ataxia (FA), a rare, hereditary neurodegenerative disease...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS